Atherosclerosis burden and progression predict all-cause mortality

A study carried out at Mount Sinaí Fuster Heart Hospital in New York in collaboration with the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid provides important new information about atherosclerosis, a disease in which lipids (cholesterol) and other substances accumulate in plaques on the arterial wall, causing the vessels to harden and narrow, and increasing the risk of severe cardiovascular conditions.

Reunion Neuroscience Inc. to Participate in October Investor Conferences | Psychedelic Invest

Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that

October 5, 2023

PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – February 8, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), is pleased to announce the closing

February 9, 2024

US FDA approves Novartis’ Fabhalta in IgAN treatment

IgA nephropathy is a rare, progressive kidney disease . Credit: crystal light/Shutterstock. Novartis has secured US Food and Drug Administration (FDA) accelerated approval for Fabhalta

August 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.